Rosebud Biosciences (YC W22) — Growing micro-organs to find new drugs
Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments.
Rosebud Biosciences is a Y Combinator company in the Winter 2022 batch. Its directory entry describes it as: Growing micro-organs to find new drugs. The founders listed are Kitch Wilson (Founder), Evan Lyall (Founder) (Y Combinator directory entry, March 7, 2022).
Get an email when Rosebud Biosciences changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.
Kitch Wilson
Founder
Evan Lyall
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 60 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Rosebud Biosciences?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rosebud Biosciences: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rosebud Biosciences covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Rosebud Biosciences: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
